Engineered immune cells take aim at childhood cancer

NCT ID NCT06865664

First seen Oct 31, 2025 · Last updated Jun 12, 2026 · Updated 30 times

Summary

This early-phase trial tests a new treatment for children and young adults (ages 3–39) with rhabdomyosarcoma that has come back or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry the FGFR4 protein. The goal is to find the safest dose and see if the cells can shrink tumors, with close monitoring for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.